Ankylosing SpondyloarthritisPhase 3POSTURENCT01583374
Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis
A Phase 3 study testing Apremilast tablet 20 mg and Apremilast tablet 30 mg BID in people with Ankylosing Spondyloarthritis, run by Amgen at 103 sites in 18 countries.
Trial summary
Apremilast is a new, orally available, small molecule drug that specifically inhibits phosphodiesterase 4 (PDE4), an enzyme that modulates inflammatory cytokines. This clinical study tests whether apremilast can improve the signs and symptoms of ankylosing spondylitis. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Ankylosing Spondyloarthritis
- What is being tested?
- Apremilast tablet 20 mg and Apremilast tablet 30 mg BID
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 490 participants
- Where
- 103 sitesin 18 countries
- Study dates
- 2 May 2012to 25 Oct 2018
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Must have a documented diagnosis of ankylosing spondylitis as defined by low back pain and stiffness, which improves with exercise, but is not relieved by rest for more than 3 months prior to screening. At the completion of screening procedures, a documented diagnosis of definite active AS, as defined by the modified New York criteria (1984) whereby both criteria, at least 1 radiographic criterion and at least 1 clinical criterion, must be met
- Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is ≥ 4
- Total back pain is ≥ 4
- On stable dose of AS medication (or lack of medication) prior to randomization and through week 24
Who cannot join
- Prior treatment with a Tumor Necrosis Factor (TNF) blocker and any biologic treatment for AS
Trial locations and contacts
103 sites in 18 countries.
103 sites in 18 countries
United States20 sites
Austin Regional Clinic
Austin, Texas, 78731
Northwestern Medical Faculty Foundation
Chicago, Illinois, 60611
MetroHealth Medical Systems
Cleveland, Ohio, 44109
Klein and Associates MD, PA
Cumberland, Maryland, 21502
STAT Research, Inc.
Dayton, Ohio, 45417
Altoona Center for Clinical Research
Duncansville, Pennsylvania, 16635
Saint Paul Rheumatology, PA
Eagan, Minnesota, 55121
Rheumatology and Immunotherapy Center
Franklin, Wisconsin, 53132
Klein and Associates MD, PA
Hagerstown, Maryland, 21740
The Arthritis Clinic
Jackson, Tennessee, 38305
University of California, San Diego
La Jolla, California, 92093-0943
Ramesh C Gupta MD
Memphis, Tennessee, 38119
Desert Medical Advances
Palm Desert, California, 92260
Sun Valley Arthritis Center
Peoria, Arizona, 85381
Advent Clinical Research Centers, Inc
Pinellas Park, Florida, 33781
University of Utah Hospitals and Clinics
Salt Lake City, Utah, 84132
UCSF Arthritis Center
San Francisco, California, 94143-0326
Burnette & Silverfield, MDS PLC
Tampa, Florida, 33614
Alastair Kennedy, MD Research
Vero Beach, Florida, 32960
Clinical Pharmacology Study Group
Worcester, Massachusetts, 01605
Canada9 sites
Clinic: University of Calgary Heritage Medical Research Clinic (HMRC),Teaching Research and Wellness (TRW)
Calgary, Alberta, T2N 4Z6
Cividino Medicine Professional Corporation
Hamilton, Ontario, L8N 2B6
Dr. William G. Bensen Medicine Professional Corporation
Hamilton, Ontario, L8N1Y2
Credit Valley Professional Building
Mississauga, Ontario, L5M 2V8
The Arthritis Program Research Group Inc.
Newmarket, Ontario, L3Y 3R7
Rheumatology Research Associates
Ottawa, Ontario, K1H1A2
Centre de Recherche Saint-Louis
Saint-Louis, Quebec, G1W 4R4
Nexus Clinical Research
St. John's, Newfoundland and Labrador, A1A 5EB
Toronto Western Hospital
Toronto, Ontario, M5T 258
Czechia8 sites
Revmatologie s.r.o.
Brno, 638 00
ARTMEDI UPD s.r.o.
Hostivice, 253 01
ARTHROMED s.r.o.
Pardubice, 530 02
Revmatologicka Ambulance
Prague, 140 00
Fakultni Thomayerova nemocnice s poliklinikou - Klinicko-farmakologicka jednotka
Prague, 140 59
Medifin a.s, Šustova
Prague, 148 00
Revmatologicka Ambulance
Sokolov, 356 01
PV-Medical s.r.o.
Zlín, 760 01
Poland8 sites
Gabinet Internistyczno-Reumatologiczny Piotr Adrian Klimiuk
Bialystok, 15-099
NZOZ Osteo-Medic sc A. Racewicz J. Supronik
Bialystok, 15-351
Szpital Uniwersytecki nr 2 im. Dr Jana Biziela w Bydgoszczy
Bydgoszcz, 85-168
Synexus SCM Sp. z o.o.
Gdynia, 81-537
Zespol Poradni Specjalistycznych
Lublin, 20-582
Prywatna Praktyka Lekarska Pawel Hrycaj
Poznan, 61-397
NZOZ NASZ LEKARZ Praktyka Grupowa Lekarzy Rodzinnych z Przychodnia Specjalistyczna
Torun, 87-100
Synexus SCM Sp. z o.o.
Wroclaw, 50-088
Russia7 sites
Research Medical Complex Vashe Zdorovie
Kazan', 420103
Kemerovo Regional Clinical Hospital
Kemerovo, 650066
Federal State Budget Institution "Rheumatology Research Institute RAMS"
Moscow, 115522
Nizhniy Novgorod State Medical Academy of Roszdrav
Nizhny Novgorod, 603005
Departmental Hospital at Smolensk Station RZhD JSC
Smolensk, 214025
Regional Clinical Hospital
Vladimir, 600023
Sverdlovsk Regional Clinical Hospital 1
Yekaterinburg, 620102
Germany6 sites
Charite - Universitätsmedizin Berlin
Berlin, 12203
Universitatsklinikum Erlangen
Erlangen, 91054
Centrum fur innovative Diagnostik und Therapie Rheumatologie Immunologie GmbH
Frankfurt, 60528
Schön Klink Hamburg-Eilbek
Hamburg, 22081
Universitatsklinikum Heidelberg
Heidelberg, 69120
Rheumazentrum Ruhrgebiet
Herne, 44649
Spain6 sites
Hospital Universitario a Coruna
A Coruña, 15006
Hospital de Bellvitge
Barcelona, 08907
Hospital Universitario Reina Sofia
Córdoba, 14001
Hospital General Universitario Gregorio Maranon
Madrid, 28007
Corporacio Sanitaria Parc Tauli de Sabadell
Sabadell, 08208
Complejo Hospitalario Universitario de Santiago de Compostela Travesía de la Choupana s/n
Santiago de Compostela, 15706
Australia5 sites
Emeritus Research
Camberwell, Victoria, 3124
Southern Clinical Research
Hobart, Tasmania, 7000
Coastal Joint Care
Maroochydore, 4558
Royal Perth Hospital
Perth, 6849
The Queen Elizabeth Hospital
Woodville South, 5011
Bulgaria5 sites
Diagnostic and Consulting Center Sv. Pantaleymon
Pleven, 5800
National Multiprofile Transport Hospital Tzar Boris III
Sofia, 1233
17 Diagnostic and Consulting Centre
Sofia, 1505
Military Medical Academy - MHAT
Sofia, 1606
Diagnostic Consulting Center N4
Varna, 9010
France5 sites
Hopital Ambroise-Pare
Boulogne, 92100
Hopital Henri Mondor
Créteil, 94010
IPROS - CHR ORLEANS - Hôpital de la Source
Orléans, 45067
Hopital Cochin
Paris, 75014
Groupe Hospitalier Pitié- Salpétrière
Paris, 75651
Hungary5 sites
Qualiclinic kft
Budapest, 1036
Synexus Magyarország Kft.
Budapest, 1036
Debreceni Egyetem Orvos- es Egeszsegtudomanyi Centrum
Debrecen, 4032
Pest Megyei Flor Ferenc Korhaz
Kistarcsa, 2143
Veszprem Megyei Csolnoky Ferenc Korhaz-Rendelointezet
Veszprém, 8200
Romania5 sites
Cristei R. Rodica - Private Medical Practice
Brăila, 810019
Sf. Maria Clinical Hospital
Bucharest, 011172
Emergency County Clinical Hospital
Cluj-Napoca, 400006
Sf Apostol Andrei Emergency Clinical County Hospital
Galati, 800578
RK Medcenter SRL
Iași, 700127
Estonia4 sites
Innomedica Medical and Research Centre
Tallinn, 10117
East Tallinn Central Hospital
Tallinn, 11412
Clinical Research Centre Ltd
Tartu, 50106
Tartu University Hospital
Tartu, 51014
United Kingdom4 sites
Barnsley Hospital
Barnsley, S75 2EP
Royal National Hospital for Rheumatic Diseases
Bath, BA1 1RL
Chapel Allerton Hospital
Leeds, LS7 4SA
Nuffield Orthopaedic Centre
Oxford, OX3 7LD
Netherlands2 sites
Leiden Universitair Medisch Centrum
Leiden, 2333 ZA
Academisch Ziekenhuis Maastricht
Maastricht, 6229 HX
Slovakia2 sites
Narodny ustav reumatickych chorob
Piešťany, 921 12
MUDr. Zuzana Cizmarikova, s.r.o., Reumatologick ambulancia
Poprad, 058 01
About this study
Official title: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF APREMILAST (CC-10004) IN THE TREATMENT OF ACTIVE ANKYLOSING SPONDYLITIS
Apremilast is a new, orally available, small molecule drug that specifically inhibits phosphodiesterase 4 (PDE4), an enzyme that modulates inflammatory cytokines. This clinical study tests whether apremilast can improve the signs and symptoms of ankylosing spondylitis.
Read the detailed description
Patients were randomized in a 1:1:1 ratio to placebo, apremilast 20 mg BID and apremilast 30 mg BID. The duration of the study was approximately 5 years. The double blind period (when patients nor the physician knew whether placebo or apremilast was taken) was 24 weeks. At Week 16, participants who did not have either a ≥ 20% improvement or a ≥ 1 unit improvement from baseline in at least two of the four SpondyloArthritis international Society (ASAS) domains were entered in "early escape" from their current treatment in a double-blinded manner. However, such participants were permitted to continue in the study. At Week 24, participants may have entered a long-term extension phase for up to an additional 4.5 years (236 weeks). At "second escape" (at Week 24), apremilast 20 mg BID treated participants transitioned to receive double-blinded apremilast 30 mg BID and remained on double-blinded apremilast 30 mg BID because they continued to improve with a longer duration of treatment. After Week 24 and during the early portion of the long-term extension through Week 52, all participants continued on either double-blinded apremilast 20 mg BID or 30 mg BID treatment. After all participants had completed Week 52 or had terminated early from the study and the 52-week data base was locked, apremilast 20 mg BID or 30 mg BID treatment was provided.
- Conditions
- Ankylosing Spondyloarthritis
- Being tested
- Apremilast tablet 20 mg, Apremilast tablet 30 mg BID, Placebo
- Keywords
- spondylitis, spondyloarthritis, Spondyloarthropathy, Oral preparation
- Medical subject headings
- Spondylitis, Ankylosing, Spondylitis, Spondylarthritis, Spondylarthropathies
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Apremilast tablet 20 mgDrug
Also called Otezla; CC-10004
Apremilast 20 mg was taken orally twice a day (BID)
Apremilast tablet 30 mg BIDDrug
Also called Otezla; CC-10004
Apremilast 30 mg was taken orally twice a day
PlaceboDrug
Identically matched placebo tablets were taken orally twice a day during the placebo controlled phase.
| Study group | Role | What they receive |
|---|---|---|
| Apremilast 20 mg | Experimental | Apremilast 20 mg was taken orally twice a day (BID) Receives: Drug: Apremilast tablet 20 mg |
| Apremilast 30 mg | Experimental | Apremilast 30 mg was taken orally twice a day Receives: Drug: Apremilast tablet 30 mg BID |
| Placebo | Placebo comparator | Identically matched placebo tablets were taken orally twice a day Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS 20) Response at Week 16
ASAS 20 was defined as achieving an improvement from baseline of ≥ 20% and ≥ 1 unit in at least 3 of 4 ASAS domains on a scale of 0 to 10 units and no worsening from baseline of ≥ 20% and ≥ 1 unit in the remaining ASAS domain on a scale of 0 to 10 units. The 4 ASAS domains are:
- Patient Global Assessment of Disease (0 - 10 unit Numerical Rating Scale [NRS]); participant marks a box with an X on a 0 - 10 unit NRS; the left-hand box of 0 = not active and the right-hand box = very active
- Total Back Pain (0 to 10 unit NRS); participant marks a box with an X on a 0 - 10 unit NRS; the left-hand box of 0 = "no pain" and the right-hand box = "most severe pain"
- Function (Bath AS Functional Index [BASFI] NRS 0 - 10 unit); participant provides a self-administered survey of 10 questions assessing for degree of mobility and functional ability
- Inflammation domain is determined by the mean of 2 Bath AS Disease Activity Index NRS Questions #5 and #6 for morning stiffness) (0 - 10 unit)
Measured: Baseline and Week 16
Secondary outcomes (9)
Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 24
The BASFI is a composite score based on a self-administered survey of 10 questions using a 0 to 10 unit numerical rating scale (NRS) that assesses the degree of mobility and functional ability. The survey consists of 8 questions regarding function in AS and the last 2 reflect the ability to manage everyday life. The patient marks a box with an X on a 0 to 10 unit NRS for 10 questions; the left-hand box of 0 = easy; the right-hand box = impossible. The resulting 0 to 100 score is divided by 10 to give a final 0 to 10 BASFI score. The overall score is the mean of the 10 items and ranges from 0 to 10. A higher score correlates to reduced functional ability.
Measured: Baseline and Week 24
Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 24
The BASDAI is a composite score based on a participant self-administered survey of six questions measured using a 0 to 10 unit numerical rating scale (NRS) that assessed the participants' five major symptoms of AS: 1) fatigue; 2) spinal pain; 3) peripheral joint pain/swelling; 4) areas of localized tenderness; 5a) morning stiffness severity upon wakening; 5b) morning stiffness duration upon wakening. The participant was asked to mark the box with an X on a 0 to 10 unit NRS for each of the 6 questions. To give each of the five symptoms equal weighting, the mean of the two scores relating to morning stiffness was taken. The resulting 0 to 50 score was divided by 5 to give a final 0 to 10 BASDAI score. A BASDAI score of 4 or greater was considered to be indicative of active AS disease.
Measured: Baseline and Week 24
Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS) Response at Week 24
ASAS 20 was defined as achieving an improvement from baseline of ≥ 20% and ≥ 1 unit in at least 3 of 4 ASAS domains on a scale of 0 to 10 units and no worsening from baseline of ≥ 20% and ≥ 1 unit in the remaining ASAS domain on a scale of 0 to 10 units. The 4 ASAS domains are:
- Patient Global Assessment of Disease (0 - 10 unit Numerical Rating Scale [NRS]); participant marks a box with an X on a 0 - 10 unit NRS; the left-hand box of 0 = not active and the right-hand box = very active
- Total Back Pain (0 to 10 unit NRS); participant marks a box with an X on a 0 - 10 unit NRS; the left-hand box of 0 = "no pain" and the right-hand box = "most severe pain"
- Function (Bath AS Functional Index [BASFI] NRS 0 - 10 unit); participant provides a self-administered survey of 10 questions assessing for degree of mobility and functional ability
- Inflammation domain is determined by the mean of 2 Bath AS Disease Activity Index NRS Questions #5 and #6 for morning stiffness) (0 - 10 unit)
Measured: Baseline and Week 24
Change From Baseline in the Ankylosing Spondylitis Quality of Life (ASQoL) Summary Score at Week 24
The ASQoL is a validated disease specific patient reported outcomes instrument to assess the impact of ankylosing spondylitis on the quality of life of individuals with emphasis on the ability of the person to fulfill his or her needs. It consisted of 18 items requesting a yes (score=1) or no (score=0) response to questions related to the impact of pain on sleep, mood, motivation, ability to cope, activities of daily living, independence, relationships, and social life. The summary score ranges 0-18 with higher scores indicating worse quality of life.
Measured: Baseline and Week 24
Change From Baseline in the Physical Component Summary Score (PCS) of Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) at Week 24
The Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) was a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). Norm-based scores (based on US general population with mean of 50 and standard deviation of 10) were used in analyses. Higher scores indicate a higher level of functioning. The PCS encompasses physical functioning, role-physical, and bodily pain, as well as general health and vitality. A positive change from baseline score indicates an improvement
Measured: Baseline and Week 24
Change From Baseline in Bath Ankylosing Spondylitis Metrology Index-Linear (BASMI-Linear) at Week 24
The BASMI-Linear was designed to assess axial status (ie, cervical, dorsal and lumbar spine, hips, and pelvic soft tissue) and to define clinically significant changes in spinal movement. Five dimensions of movement (lateral lumbar flexion, tragus to wall, forward lumbar flexion, maximal intermalleolar distance, and cervical rotation) were measured and normalized on 0 to 10 unit NRS. The average of these scores was the total BASMI score, ranging from 0-10 with higher values indicating more severe limitation in spinal mobility.
Measured: Baseline and Week 24
Change From Baseline in the Radiographic Score Using the Modified Stoke Ankylosing Spondylitis Spine Score (m-SASSS) at Week 104 and Week 260
The Modified Stoke Ankylosing Spondylitis Spine Score is a scoring method used to determine the amount or degree of ankylosing spondylitis disease that is in the spine based on x-ray radiographs of the spine. The m-SASSS scores 0-3.
0 = No abnormality, 1 = Erosion, Sclerosis or Squaring, 2 = Syndesmophyte, 3 = Total bony Bridging at each Site. An increase in the m-SASSS indicated a worsening of AS disease.
Measured: Baseline to Week 104 and 260
Number of Participants With Treatment Emergent Adverse Events (TEAEs) During the Placebo Controlled Phase
A TEAE was an adverse event (AE) with a start date on or after the date of the first dose of IP and no later than 28 days after the last dose of IP for participants who discontinued early. A serious AE = results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect; or constitutes an important medical event. The severity of AEs was assessed based on the following scale: Mild = asymptomatic or mild symptoms, clinical or diagnostic observations only; Moderate = symptoms cause moderate discomfort; Severe = symptoms causing severe pain discomfort.
Measured: From Week 0 to Week 24; the median duration of exposure was 23.57 weeks for the placebo arm, 23.71 weeks for the apremilast 20 mg arm and 24.00 weeks for the apremilast 30 mg arm.
Number of Participants With Treatment Emergent Adverse Events During the Apremilast Exposure Period
A TEAE was an adverse event (AE) with a start date on or after the date of the first dose of IP and no later than 28 days after the last dose of IP for participants who discontinued early. A serious AE = results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect; or constitutes an important medical event. The severity of AEs was assessed based on the following scale: Mild = asymptomatic or mild symptoms, clinical or diagnostic observations only; Moderate = symptoms cause moderate discomfort; Severe = symptoms causing severe pain discomfort.
Measured: Week 0 to week 260; overall mean duration of exposure to apremilast 20 mg and 30 mg BID was 160.96 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Apr 2012 (estimated)
- Study start2 May 2012
- Primary completion24 Feb 2014
- Study completion25 Oct 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Ankylosing SpondyloarthritisStudies of the same condition, open and under way.
- More trials run by AmgenThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 490 participants (actual)
Sponsor and investigators
- Lead sponsor
- Amgen
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- MD, Study director, Amgen
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01583374
- Sponsor's protocol ID
- CC-10004-AS-001
- Other IDs
- 2011-001555-37
- Acronym
- POSTURE
- Status last verified
- Oct 2019
- First submitted
- 20 Apr 2012
- Last updated
- 12 May 2020
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- Individual data sharing
- Yes: De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
Publications
Gladman DD, Kavanaugh A, Gomez-Reino JJ, Wollenhaupt J, Cutolo M, Schett G, Lespessailles E, Guerette B, Delev N, Teng L, Edwards CJ, Birbara CA, Mease PJ. Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1-3 studies. RMD Open. 2018 Jun 27;4(1):e000669. doi: 10.1136/rmdopen-2018-000669. eCollection 2018.
PubMed 30018799Kavanaugh A, Gladman DD, Edwards CJ, Schett G, Guerette B, Delev N, Teng L, Paris M, Mease PJ. Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis. Arthritis Res Ther. 2019 May 10;21(1):118. doi: 10.1186/s13075-019-1901-3.
PubMed 31077258Taylor PC, van der Heijde D, Landewe R, McCue S, Cheng S, Boonen A. A Phase III Randomized Study of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Active Ankylosing Spondylitis. J Rheumatol. 2021 Aug;48(8):1259-1267. doi: 10.3899/jrheum.201088. Epub 2021 Feb 15.
PubMed 33589554
Study at a glance
From the registry record, last updated by the sponsor on 12 May 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF APREMILAST (CC-10004) IN THE TREATMENT OF ACTIVE ANKYLOSING SPONDYLITIS
- ClinicalTrials.gov ID
- NCT01583374
- Acronym / sponsor ID
- POSTURE / CC-10004-AS-001
- Conditions
- Ankylosing Spondyloarthritis
- Keywords
- spondylitis, spondyloarthritis, Spondyloarthropathy, Oral preparation
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 490 participants (actual)
- Lead sponsor
- AmgenIndustry (pharma, biotech, devices)
- Study start
- 2 May 2012 (actual)
- Primary completion
- 24 Feb 2014 (actual)
- Study completion
- 25 Oct 2018 (actual)
- First posted
- 24 Apr 2012 (estimated)
- Results
- Posted 17 Mar 2015
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Apremilast is a new, orally available, small molecule drug that specifically inhibits phosphodiesterase 4 (PDE4), an enzyme that modulates inflammatory cytokines. This clinical study tests whether apremilast can improve the signs and symptoms of ankylosing spondylitis.
Detailed description
Patients were randomized in a 1:1:1 ratio to placebo, apremilast 20 mg BID and apremilast 30 mg BID. The duration of the study was approximately 5 years. The double blind period (when patients nor the physician knew whether placebo or apremilast was taken) was 24 weeks. At Week 16, participants who did not have either a ≥ 20% improvement or a ≥ 1 unit improvement from baseline in at least two of the four SpondyloArthritis international Society (ASAS) domains were entered in "early escape" from their current treatment in a double-blinded manner. However, such participants were permitted to continue in the study. At Week 24, participants may have entered a long-term extension phase for up to an additional 4.5 years (236 weeks). At "second escape" (at Week 24), apremilast 20 mg BID treated participants transitioned to receive double-blinded apremilast 30 mg BID and remained on double-blinded apremilast 30 mg BID because they continued to improve with a longer duration of treatment. After Week 24 and during the early portion of the long-term extension through Week 52, all participants continued on either double-blinded apremilast 20 mg BID or 30 mg BID treatment. After all participants had completed Week 52 or had terminated early from the study and the 52-week data base was locked, apremilast 20 mg BID or 30 mg BID treatment was provided.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Apremilast 20 mg | Experimental | Drug: Apremilast tablet 20 mgApremilast 20 mg was taken orally twice a day (BID) |
| Apremilast 30 mg | Experimental | Drug: Apremilast tablet 30 mg BIDApremilast 30 mg was taken orally twice a day |
| Placebo | Placebo comparator | Drug: PlaceboIdentically matched placebo tablets were taken orally twice a day |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Must have a documented diagnosis of ankylosing spondylitis as defined by low back pain and stiffness, which improves with exercise, but is not relieved by rest for more than 3 months prior to screening. At the completion of screening procedures, a documented diagnosis of definite active AS, as defined by the modified New York criteria (1984) whereby both criteria, at least 1 radiographic criterion and at least 1 clinical criterion, must be met
- Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is ≥ 4
- Total back pain is ≥ 4
- On stable dose of AS medication (or lack of medication) prior to randomization and through week 24
Key exclusion criteria (1 listed)
- Prior treatment with a Tumor Necrosis Factor (TNF) blocker and any biologic treatment for AS
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Apremilast tablet 20 mgAlso: Otezla; CC-10004Apremilast 20 mg was taken orally twice a day (BID) | Drug | Apremilast 20 mg |
| Apremilast tablet 30 mg BIDAlso: Otezla; CC-10004Apremilast 30 mg was taken orally twice a day | Drug | Apremilast 30 mg |
| PlaceboIdentically matched placebo tablets were taken orally twice a day during the placebo controlled phase. | Drug | Placebo |
Primary outcome
Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS 20) Response at Week 16
Time frame: Baseline and Week 16
ASAS 20 was defined as achieving an improvement from baseline of ≥ 20% and ≥ 1 unit in at least 3 of 4 ASAS domains on a scale of 0 to 10 units and no worsening from baseline of ≥ 20% and ≥ 1 unit in the remaining ASAS domain on a scale of 0 to 10 units. The 4 ASAS domains are: 1. Patient Global Assessment of Disease (0 - 10 unit Numerical Rating Scale [NRS]); participant marks a box with an X on a 0 - 10 unit NRS; the left-hand box of 0 = not active and the right-hand box = very active 2. Total Back Pain (0 to 10 unit NRS); participant marks a box with an X on a 0 - 10 unit NRS; the left-hand box of 0 = "no pain" and the right-hand box = "most severe pain" 3. Function (Bath AS Functional Index [BASFI] NRS 0 - 10 unit); participant provides a self-administered survey of 10 questions assessing for degree of mobility and functional ability 4. Inflammation domain is determined by the mean of 2 Bath AS Disease Activity Index NRS Questions #5 and #6 for morning stiffness) (0 - 10 unit)
9 secondary outcomes
Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 24
Time frame: Baseline and Week 24
Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 24
Time frame: Baseline and Week 24
Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS) Response at Week 24
Time frame: Baseline and Week 24
Change From Baseline in the Ankylosing Spondylitis Quality of Life (ASQoL) Summary Score at Week 24
Time frame: Baseline and Week 24
Change From Baseline in the Physical Component Summary Score (PCS) of Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) at Week 24
Time frame: Baseline and Week 24
Change From Baseline in Bath Ankylosing Spondylitis Metrology Index-Linear (BASMI-Linear) at Week 24
Time frame: Baseline and Week 24
Change From Baseline in the Radiographic Score Using the Modified Stoke Ankylosing Spondylitis Spine Score (m-SASSS) at Week 104 and Week 260
Time frame: Baseline to Week 104 and 260
Number of Participants With Treatment Emergent Adverse Events (TEAEs) During the Placebo Controlled Phase
Time frame: From Week 0 to Week 24; the median duration of exposure was 23.57 weeks for the placebo arm, 23.71 weeks for the apremilast 20 mg arm and 24.00 weeks for the apremilast 30 mg arm.
Number of Participants With Treatment Emergent Adverse Events During the Apremilast Exposure Period
Time frame: Week 0 to week 260; overall mean duration of exposure to apremilast 20 mg and 30 mg BID was 160.96 weeks
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 May 2020.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Background: PubMed 30018799Gladman DD, Kavanaugh A, Gomez-Reino JJ, Wollenhaupt J, Cutolo M, Schett G, Lespessailles E, Guerette B, Delev N, Teng L, Edwards CJ, Birbara CA, Mease PJ. Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1-3 studies. RMD Open. 2018 Jun 27;4(1):e000669. doi: 10.1136/rmdopen-2018-000669. eCollection 2018.
- Background: PubMed 31077258Kavanaugh A, Gladman DD, Edwards CJ, Schett G, Guerette B, Delev N, Teng L, Paris M, Mease PJ. Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis. Arthritis Res Ther. 2019 May 10;21(1):118. doi: 10.1186/s13075-019-1901-3.
- Derived from this study: PubMed 33589554Taylor PC, van der Heijde D, Landewe R, McCue S, Cheng S, Boonen A. A Phase III Randomized Study of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Active Ankylosing Spondylitis. J Rheumatol. 2021 Aug;48(8):1259-1267. doi: 10.3899/jrheum.201088. Epub 2021 Feb 15.
- Individual participant dataSharing planned: Yes. De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
Related trials for Ankylosing Spondyloarthritis
RecruitingPhase 1
A Study of HB0017 Injection in Healthy Volunteers to Evaluate Safety and Tolerability of a Single Subcutaneous Injection in Low-Body-Weight Subjects; and Pharmacokinetics at Different Subcutaneous Injection Sites at the Same Dose
Psoriasis, Ankylosing Spondylitis
RecruitingObservational study
Pain Phenotyping of Rheumatic Diseases - An Observational Study
Rheumatic Diseases, Lupus Erythematosus, Systemic
RecruitingObservational study
Identification of Serum Level of Glutathione Peroxidase 4
Spondyloarthropathy
Not yet recruitingPhase 1
A Study of GKL-006Allo Injection in Patients With Ankylosing Spondylitis
Ankylosing Spondylitis
Active, not recruitingObservational study
Neuropathic Spinal Pain in Ankylosing Spondylitis
Ankylosing Spondylitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
MD study director
Amgen
103 sites in 18 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Apremilast tablet 20 mg and Apremilast tablet 30 mg BID in people with Ankylosing Spondyloarthritis, run by Amgen at 103 sites in 18 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 12 May 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 103 sites in United States, Canada, Czechia, Poland, Russia and 13 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 17 Mar 2015). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS 20) Response at Week 16 (time frame: Baseline and Week 16). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01583374, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 May 2020.